We identified USP17 as a novel deubiquitinating enzyme regulating c-Myc levels to control cell proliferation. Overexpression of USP17 stabilized the c-Myc protein by promoting its deubiquitination ...

About c-MYC c-MYC is a well-validated oncogene with broad anti-cancer potential, as c-MYC expression is dysregulated in more than 70% of cancers and a key regulator in nearly every aspect of ...

During the progression of gastric cancer, genetic factors play an indispensable role. c-Myc, an oncogene, is abnormally highly expressed in a variety of tumors, including gastric cancer.

These findings are the first to identify a cancer-inhibiting relationship between the proteins. “We found that RBM10 can directly target c-Myc for degradation and reduce its cancer-causing ...

Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions ...

Besides, c-Myc is also known as a factor necessary for the initial induction of iPS cells. In the future this inhibition can be expected to be applied as a technology that can also be used to ...

Dr. Chidiebere Awah, MD, PhD, CEO of UTR Therapeutics Inc. shares his approach on revolutionizing cancer care NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc (UTRx Inc.), a drug ...

In the upcoming human trial, UTRxM1-18 will be used to target c-MYC driven tumors including triple negative breast cancer, pancreatic cancer, colorectal cancer and ovarian cancer. In animal studies, ...